ADCOCK INGRAM HLDGS LTDAA

ADCOCK INGRAM HLDGS LTD

5,059ZACR
−10−0.20%
At close at May 23, 15:00 GMT
ZAC
No trades
See on Supercharts

AIP fundamentals

Key facts

Market capitalization‪8.18 B‬ZAR
Founded1890
CEOAndrew Gideon Hall
About

Adcock Ingram Holdings Ltd. is a pharmaceutical company, which engages in the manufacture, marketing, and distribution of healthcare products to both private and public sectors of the market. It operates through the following segments: Consumer, Over the Counter (OTC), Prescription, Hospital, and Other Shared Services. The Consumer segment competes in the Fast-Moving Consumer Goods space. The OTC segment focuses on brands sold predominantly in pharmacy, where the pharmacist plays a role in the product choice. The Prescription segment offers products prescribed by medical practitioners, specialized instruments, and surgical products. The Hospital segment supplies hospital and critical care products, including intravenous solutions, blood collection products, and renal dialysis systems. The Other Shared Services segment refers to other support services, including the regulatory services in India, as well as the investment in the Indian joint venture and cash and bank overdraft balances which are managed on a central basis in Southern Africa. The company was founded in 1890 and is headquartered in Midrand, South Africa.

Ownership
‪‪155.18 M‬‬
Closely held shares
‪‪100.29 M‬‬ (64.63%)
Free Float shares
‪‪54.89 M‬‬ (35.37%)
Closely held shares
‪‪100.29 M‬‬ (64.63%)
Free Float shares
‪‪54.89 M‬‬ (35.37%)
Capital structure
Market cap
‪‪8.18 B‬‬
Debt
‪‪969.40 M‬‬
Minority interest
‪‪−55.00 K‬‬
Cash & equivalents
‪‪79.14 M‬‬
Enterprise value
‪‪9.07 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪8.18 B‬‬
Price to earning ratio (P/E)
10.18x
Price to sales ratio (P/S)
0.80x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
10.18x
Price to sales ratio (P/S)
0.80x
Valuation ratios
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
‪1.20‬
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪3.50‬
‪7.00‬
‪10.50‬
‪14.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪7.5%‬
‪8.2%‬
‪8.9%‬
‪9.6%‬
‪10.3%‬
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪1.30 B‬‬
‪‪2.60 B‬‬
‪‪3.90 B‬‬
‪‪5.20 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬
‪‪3.60 B‬‬
‪‪4.80 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬
‪‪3.60 B‬‬
‪‪4.80 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Prescription
Over the Counter
Hospital
Consumer
Other - Shared Services
By country
Period: 2024
Southern Africa

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '25
H2 '25
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬
‪‪3.60 B‬‬
‪‪4.80 B‬‬
Actual
Earnings
Next:Aug 20, 2025
H1 '25
H2 '25
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Actual

Dividends

Dividend yield, history and sustainability

Dividend summary
51.57%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
5.24%
Last payment
1.15
Last ex-date
Mar 12, 2025
Last pay date
Mar 17, 2025
Dividend history
‪2.0%‬
‪2.7%‬
‪3.4%‬
‪4.1%‬
‪4.8%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
‪2.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪‪−350.00 M‬‬
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬
Assets
Liabilities